The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma
Michail N Mavros, Farah Ladak, Kelvin K W Chan, Lena Nguyen, Natalie G Coburn, Michael J Raphael · 2026
Read The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma by Michail N Mavros, Farah Ladak, Kelvin K W Chan, Lena Nguyen, Natalie G Coburn, Michael J Raphael (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13161621.txt.
Description
Michail N Mavros and co-authors explored, in a 2026 study, whether heart drugs track with longer survival in advanced pancreatic cancer. The cancer kills fast and offers few treatment options. Older lab and record studies hint that blood pressure drugs of one class and cholesterol drugs called statins might boost chemo.
Ontario registry data covered 3,226 patients aged 67 and up on first-line chemo between 2015 and 2024. Forty-one percent took both drug types, while 28 percent took neither. Median survival sat at 7.9 months across groups. Careful models treated drug exposure as time-varying to dodge a known bias. The authors frame the work as hypothesis-generating: a cheap, safe add-on signal worth a proper trial, not yet a proven aid.
Catalog record
| CREATOR | Michail N Mavros, Farah Ladak, Kelvin K W Chan, Lena Nguyen, Natalie G Coburn, Michael J Raphael |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |